Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejphar.2020.173326 http://scihub22266oqcxt.onion/10.1016/j.ejphar.2020.173326 32598953!7319927!32598953     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Pharmacol 2020 ; 883 (ä): 173326 Nephropedia Template TP {{tp|p=32598953|t=2020. Drug treatment of coronavirus disease 2019 (COVID-19) in China |pdf=|usr=}}{{32598953}} gab.com Text Drug treatment of coronavirus disease 2019 (COVID-19) in China JO: Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32598953 #FOAvip Since December 2019, the coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout China as well as other countries. More than 8,700,000 confirmed COVID-19 cases have been recorded worldwide so far, with much more cases popping up overseas than those inside. As the initial epicenter in the world, China has been combating the epidemic for a relatively longer period and accumulated valuable experience in prevention and control of COVID-19. This article reviewed the clinical use, mechanism and efficacy of the clinically approved drugs recommended in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (DTPNCP) released by National Health Commission of P.R.China, and the novel therapeutic agents now undergoing clinical trials approved by China National Medical Products Administration (NMPA) to evaluate experimental treatment for COVID-19. Reviewing the progress in drug development for the treatment against COVID-19 in China may provide insight into the epidemic control in other countries. Twit Text FOAVip Drug treatment of coronavirus disease 2019 (COVID-19) in China ????Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32598953 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32598953 #FOAvip English Wikipedia <ref>{{Cite pmid|32598953}}</ref> Drug treatment of coronavirus disease 2019 (COVID-19) in China #MMPMID32598953 Jin Z; Liu JY; Feng R; Ji L; Jin ZL; Li HB Eur J Pharmacol 2020[Sep]; 883 (ä): 173326 PMID32598953show ga Since December 2019, the coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout China as well as other countries. More than 8,700,000 confirmed COVID-19 cases have been recorded worldwide so far, with much more cases popping up overseas than those inside. As the initial epicenter in the world, China has been combating the epidemic for a relatively longer period and accumulated valuable experience in prevention and control of COVID-19. This article reviewed the clinical use, mechanism and efficacy of the clinically approved drugs recommended in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (DTPNCP) released by National Health Commission of P.R.China, and the novel therapeutic agents now undergoing clinical trials approved by China National Medical Products Administration (NMPA) to evaluate experimental treatment for COVID-19. Reviewing the progress in drug development for the treatment against COVID-19 in China may provide insight into the epidemic control in other countries. |*Coronavirus Infections/drug therapy/epidemiology[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/drug therapy/epidemiology[MESH] |Antiviral Agents/*pharmacology[MESH] |Betacoronavirus/drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |China/epidemiology[MESH] |Humans[MESH]Drug treatment of coronavirus disease 2019 (COVID-19) in China (epmc).pdf DeepDyve Pubget Overpricing